Scarica l'app Stockscreener
25.14
0.95%
-0.24
Dopo l'orario di chiusura:
25.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$25.38
Aprire:
$25.18
Volume 24 ore:
2.10M
Relative Volume:
1.85
Capitalizzazione di mercato:
$1.67B
Reddito:
$9.98M
Utile/perdita netta:
$-154.08M
Rapporto P/E:
-9.5227
EPS:
-2.64
Flusso di cassa netto:
$-159.66M
1 W Prestazione:
-1.06%
1M Prestazione:
-4.77%
6M Prestazione:
-29.56%
1 anno Prestazione:
-33.46%
Intervallo 1D:
$24.83
$25.95
Intervallo di 1 settimana:
$23.94
$26.66
Portata 52W:
$22.93
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Confronta CLDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
25.14 | 1.67B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
What Analysts Are Saying About Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - The Manila Times
Celldex Launches Pivotal Phase 2 Trial for Novel Atopic Dermatitis Treatment, Targeting 20% of US Population - StockTitan
State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Canada
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - Investing.com
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.5%Here's Why - MarketBeat
BNP Paribas Financial Markets Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
XTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Wellington Management Group LLP Acquires 1,167,659 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
The Manufacturers Life Insurance Company Cuts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Readystate Asset Management LP Takes $6.10 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Redmile Group LLC Cuts Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Cinctive Capital Management LP Decreases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Position Decreased by Fmr LLC - MarketBeat
Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $62.25 - MarketBeat
Prurigo Nodularis Pipeline Insights 2024: Therapies, Clinical - openPR
CBC acquires UCB’s neurology and allergy business in China - Pharmaceutical Technology
Bellevue Group AG Buys 100,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Intech Investment Management LLC Makes New $871,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Fisher Asset Management LLC Buys 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Algert Global LLC Sells 20,631 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Celldex Therapeutics' SWOT analysis: barzolvolimab stock shows promise in urticaria treatment - Investing.com
Celldex Therapeutics' SWOT analysis: barzolvolimab stock shows promise in urticaria treatment By Investing.com - Investing.com South Africa
Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Positive Forecast for CLDX FY2025 Earnings - MarketBeat
Jennison Associates LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St
Celldex Therapeutics (NASDAQ:CLDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - The Manila Times
Celldex Launches Phase 1 Trial of Novel Dual-Action Inflammatory Disease Treatment | CLDX Stock News - StockTitan
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com Canada
Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com
Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com
Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com
FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World
Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celldex Therapeutics Inc Azioni (CLDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Option Exercise |
10.16 |
20,169 |
204,990 |
45,297 |
| Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Sale |
35.42 |
17,172 |
608,315 |
28,125 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Option Exercise |
10.38 |
30,000 |
311,400 |
39,074 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Sale |
34.87 |
30,000 |
1,045,962 |
9,074 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 11 '24 |
Option Exercise |
2.71 |
15,000 |
40,650 |
17,115 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Option Exercise |
9.70 |
15,000 |
145,474 |
24,074 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Sale |
35.06 |
15,000 |
525,873 |
9,074 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 07 '24 |
Sale |
35.26 |
45,000 |
1,586,844 |
2,115 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Jun 05 '24 |
Option Exercise |
10.38 |
9,540 |
99,025 |
35,464 |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS |
Jun 03 '24 |
Option Exercise |
10.25 |
64,658 |
662,575 |
71,752 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):